Topical minoxidil for hair loss: what the evidence shows

Key points

• Topical minoxidil is sold over the counter in the US. The 5% solution label covers men only, for the crown. A 2% solution and a 5% foam carry labels that include women [1][2][3][4].
• A 48-week trial of 393 men found 5% beat 2% and placebo on hair counts, with more itching and irritation at 5%. The Cochrane review in women found no clear difference between 2% and 5% [6][11].
• Most trials last 16 to 48 weeks. We found no controlled data in this session on use over many years.
• The @Hoostethics list ranks topical minoxidil in D tier. That placement is not supported by the trial and regulatory record. Its S-tier “topical hair serum” entry is only partly checkable [18].

What it is and where it came from

Minoxidil is a vasodilator. Taken by mouth it lowers blood pressure; a 2004 review in the British Journal of Dermatology notes that it has been known “for over 30 years” to stimulate hair growth, although how it does so in the follicle is poorly understood [14]. In animal work, topical minoxidil shortens the resting phase and pushes resting follicles into the growth phase, and the review says it probably does the same in people [14].

A 1988 paper titled “The history of the development of minoxidil” was written by an author at the Upjohn Company’s Hair Growth Research Unit in Kalamazoo, Michigan [15]. We could not open its text, so we do not repeat the usual account of how the hair effect was noticed, or the dates of the original blood-pressure approval. Treat any such detail you read elsewhere as unchecked by us.

Regulatory status

All statements below are for the United States unless noted, checked on 2026-11-09.

openFDA’s Drugs@FDA records list three Kenvue applications for over-the-counter topical minoxidil [5]:

Application	Product	Original approval date in record
NDA 019501	2% solution, listed for men and for women	17 Aug 1988
NDA 020834	5% “Extra Strength” solution, for men	14 Nov 1997
NDA 021812	5% foam, listed for men and for women	20 Jan 2006

The record shows current OTC status, not when each product moved from prescription to OTC; we did not verify that date. openFDA says its data are unvalidated [5].

What the labels say:

• Men’s 5% solution: to regrow hair “on the top of the scalp (vertex only)”. Do not use if you are a woman, have no family history of hair loss, have sudden or patchy loss, are under 18, or have a red, irritated or painful scalp [1].
• Men’s 5% foam: same crown-only wording and men-only warning [3].
• Women’s 2% solution: “to regrow hair on the scalp” [2].
• Women’s 5% foam: “to regrow hair on the top of the scalp” [4]. Do not use if hair loss is sudden, patchy or linked to childbirth.

The US 5% solution is not labelled for women, even though a 5% foam is. In the UK, the Regaine for Men Extra Strength summary of product characteristics (revised 17 December 2024) is indicated for androgenetic hair loss in men and lists women as a contraindication [16]. We did not check EMA, German (BfArM) or other UK products. “Research use only” does not apply: these are licensed medicines.

What the trials found

Men, 2% vs 5% solution. Olsen and colleagues ran a 48-week, double-blind, placebo-controlled trial in 393 men aged 18 to 49 (5%: 157; 2%: 158; placebo: 78), applying the product twice daily. The 5% solution was superior to 2% and placebo for change in non-vellus (thicker) hair count, patient-rated scalp coverage and investigator-rated coverage. The authors describe “45% more hair regrowth” than 2% at week 48, and an earlier response with 5% [6]. We could not read the full text, so we cannot state the absolute counts or the funder.

Men, 5% foam. A 16-week trial of 352 men compared a propylene-glycol-free 5% foam with placebo. Hair counts and subjective assessment favoured the foam (both P < .0001); 143 men continued in an open-label extension for 52 weeks of safety data. The authors note that no efficacy data were collected beyond 16 weeks. The trial was supported by Pfizer Inc. [7][8]

Pooled men’s and mixed data. A 2015 systematic review and meta-analysis found minoxidil better than placebo for total hair growth (mean difference 16.68, 95% CI 9.34 to 24.03) and non-vellus hair growth (20.90, 95% CI 9.07 to 32.74), in the percent-increase outcome. More participants in the minoxidil groups showed greater growth by investigator (RR 2.28) and self-report (RR 1.56). The authors state that cosmetically acceptable results occur “in only a subset of patients” [12].

Women. The Cochrane review “Interventions for female pattern hair loss” (2016; searches to July 2015) included 47 trials with 5,290 women; 17 evaluated minoxidil. Only 5 trials were at low risk of bias, 26 unclear and 16 high. Pooled results:

• Moderate to marked regrowth (self-report): 157/593 on minoxidil vs 77/555 on placebo, RR 1.93 (moderate-quality evidence).
• Total hair count: 13.18 more hairs per cm² than placebo in 8 studies (1,242 women; low-quality evidence).
• 2% vs 5% (four trials, 1,006 women): no difference in hair count (mean difference -2.12, 95% CI -5.47 to 1.23) or adverse events [11].

Two later women’s trials used foam. A 24-week single-blind trial of 113 women compared 5% foam once daily with 2% solution twice daily and found the foam non-inferior on hair count and width, with less local intolerance (P = .046); participants knew which product they had [9]. A 24-week, double-blind phase III trial of 404 women found 5% foam produced 9.1 more hairs per cm² than vehicle foam at week 24 (P < .0001) [10]. We did not see funding statements for [9], [10] or [11] in the abstracts.

Foam versus solution

The 2007 men’s trial compared foam with placebo, not with solution [7]. In women, the one head-to-head trial found foam once daily not worse than 2% solution twice daily, with fewer reports of itching and dandruff [9]. Because the products differ in concentration, schedule and vehicle, the data do not isolate “foam vs solution” as a variable. We did not find a controlled head-to-head of 5% foam against 5% solution in this session.

Shedding

The literature describes an early, temporary increase in hair loss after starting. In a retrospective study of 49 people with androgenetic alopecia using 2% or 5% topical minoxidil for 24 weeks, shedding rose temporarily within the first 12 weeks, lasted longer with 2% than 5%, and its size correlated with later improvement on some measures. The authors suggest the peak could predict response. It was a small, retrospective study without a placebo arm [13]. The mechanism proposed in the 2004 review, resting follicles entering the growth phase, is consistent with this but unproven in humans [14]. The US labels we opened do not mention shedding [1][2].

Risks and unknowns

• Skin effects. In the 393-man trial, itching and local irritation were more common with 5% than 2% [6]. The US labels tell users to stop and ask a doctor for scalp irritation or redness and for unwanted facial hair growth [1][2].
• Facial hair. The UK label lists hypertrichosis as common [16]. In the women’s phase III trial, scalp irritation and facial hypertrichosis were uncommon, with no clinically significant difference from vehicle [10].
• Systemic effects. The 2002 trial reported no evidence of systemic effects [6]. US labels still tell users to ask a doctor first with heart disease, and to stop for chest pain, rapid heartbeat, faintness, dizziness, sudden weight gain or swelling of the hands or feet [1][3]. The UK label lists chest pain, palpitations and peripheral swelling among its undesirable effects [16].
• Pregnancy and breastfeeding. US labels: “May be harmful if used when pregnant or breast-feeding” [1][2][4]. The UK label says it should not be used in pregnancy or lactation [16].
• Pets. The US labels we opened do not mention animals [1]. A 2023 veterinary case report described two cats with heart injury after suspected ingestion of 5% minoxidil, both of whom recovered [17]. A 2025 scoping review of toxicosis in cats and dogs exists in the Journal of the American Academy of Dermatology; we could see only its title [17]. We did not find or open a statement from a regulator or poison-control body on pets, so we make no authority-backed claim here.
• Not studied or not found. Controlled data over many years, effects after stopping, and men’s use of foam against solution. Trials mainly enrolled adults with androgenetic alopecia; the label excludes people under 18.

For the oral tablet, see oral minoxidil. For the other approved hair-loss drug, see finasteride. For the spray sometimes grouped with serums, see topical dutasteride.

What the source post claims

On 2026-10-22 @Hoostethics posted a tier list of “looksmaxxing techniques” [18]. X returned only the caption through the fxtwitter mirror; the placements come from our transcription of the image. It puts “topical minoxidil” in D tier and a “topical hair serum” in S tier, which the image shows as a minoxidil-type serum and a “topical dutasteride” spray. The list states no criteria.

Verdict on topical minoxidil in D: not supported. It is an FDA-approved over-the-counter drug with randomized trials in hundreds of men and women, and a Cochrane review of women rating the evidence for efficacy and safety as mostly moderate to low quality [1][6][11]. A fair criticism is that the effect is modest and only a subset reach cosmetically acceptable results [12]. The list gives no reason for the placement.

Verdict on “topical hair serum” in S: could not be verified, and internally inconsistent. If the serum is minoxidil, it is the same drug as the D-tier entry, and one product cannot be both. We found no approved topical dutasteride product in this session’s checks and did not review its evidence here. The S placement is not backed by anything we could open.

Frequently asked questions

Is topical minoxidil FDA approved for women? Yes, in specific products. The 2% solution and a 5% foam carry labels for women’s hair loss, while the 5% solution label is for men only [1][2][4].

Does 5% work better than 2%? In a 393-man trial, yes on hair count and ratings, with more irritation [6]. In the Cochrane review of women, the four 2% vs 5% trials showed no difference in hair count [11].

Does minoxidil cause shedding at the start? A small retrospective study of 49 people found a temporary rise within 12 weeks [13]. Labels do not discuss it [1].

Is it safe in pregnancy? US labels warn it may be harmful in pregnancy or breastfeeding, and the UK label advises against use [1][16].

Sources

1. Kenvue, Men’s Rogaine Extra Strength Unscented (minoxidil 5% solution) label, DailyMed (version of 4 Nov 2024; label text updated 6 Sep 2024). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccaecec5-5348-4b24-9190-5464c50f6d80
2. Kenvue, Women’s Rogaine Unscented (minoxidil 2% solution) label, DailyMed (4 Nov 2024). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bf0000c-95f3-4a4d-830b-f5ac1539823d
3. Kenvue, Men’s Rogaine Unscented foam (5%) label, DailyMed (14 Nov 2024). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b5e2860-6855-4a65-8bbc-e064172a1adf
4. Kenvue, Women’s Rogaine Unscented foam (5%) label, DailyMed (15 Nov 2024). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d328537-b7f5-43cc-9837-c5a0c6c390f8
5. FDA, openFDA Drugs@FDA records for Rogaine, NDA 019501, 020834 and 021812 (queried 2026-11-09). https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:ROGAINE
6. Olsen EA et al., J Am Acad Dermatol, “A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men” (2002), abstract via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/12196747/
7. Olsen EA et al., J Am Acad Dermatol, “A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in men” (2007), abstract via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/17761356/
8. Penn State Pure record of [7], funding line “Supported by Pfizer Inc.” (read 2026-11-09). https://pure.psu.edu/en/publications/a-multicenter-randomized-placebo-controlled-double-blind-clinical/
9. “A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women” (2011), abstract via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/21700360/
10. “A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss”, J Drugs Dermatol 15(7):874-881 (2016). https://pubmed.ncbi.nlm.nih.gov/27391639/
11. Cochrane Database Syst Rev, “Interventions for female pattern hair loss” (2016), CD007628. https://pubmed.ncbi.nlm.nih.gov/27225981/
12. “Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia” (2015). https://pubmed.ncbi.nlm.nih.gov/26380504/
13. “Whether the transient hair shedding phase exist after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients” (2025), doi 10.1080/09546634.2025.2480739. https://pubmed.ncbi.nlm.nih.gov/40122142/
14. Messenger AG, Rundegren J, Br J Dermatol, “Minoxidil: mechanisms of action on hair growth” (2004). https://pubmed.ncbi.nlm.nih.gov/14996087/
15. Zins GR, “The history of the development of minoxidil” (1988), record only (no abstract). https://pubmed.ncbi.nlm.nih.gov/3063368/
16. Electronic Medicines Compendium, Regaine for Men Extra Strength Scalp Solution 5% w/v, summary of product characteristics (revised 17 Dec 2024). https://www.medicines.org.uk/emc/product/5765/smpc/print
17. “Successful management of minoxidil 5% toxicosis in 2 cats from the same household”, J Vet Emerg Crit Care (2023), https://pubmed.ncbi.nlm.nih.gov/37222073/ ; “Minoxidil toxicosis in cats and dogs: A scoping review and call to action”, J Am Acad Dermatol (2025), title only, https://pubmed.ncbi.nlm.nih.gov/40189148/
18. @Hoostethics, “ranking looksmaxxing techniques.” (22 Oct 2026). https://x.com/Hoostethics/status/2113302148750758106 (X blocked direct reading; caption read through the fxtwitter mirror, tier placements from the image transcription in our source notes).

This article is information, not medical advice.